**УДК 616.61-089.843-07:575.113.2**

**ГЕНЕТИЧЕСКИЕ ДЕТЕРМИНАНТЫ МЕТАБОЛИЗМА ТАКРОЛИМУСА, СВЯЗАННЫЕ С CYP3A5 В ТРАНСПЛАНТОЛОГИИ ПОЧЕК: ОБЗОР ЛИТЕРАТУРЫ**

А.Т. Аубакирова, И.К. Мададов, Б.Г. Ргебаев

АО «Национальный научный центр хирургии им. А.Н.Сызганова», Алматы, Республика Казахстан.

**Аннотация**

**Актуальность:** пересадка почки — наиболее эффективный метод лечения терминальной хронической почечной недостаточности, значительно улучшающий качество жизни и снижением смертности по сравнению с диализом. Успех трансплантации зависит от HLA-совместимости донора и реципиента, уровня иммунной сенсибилизации, состояния иммунной системы и подбора иммуносупрессивной терапии, предотвращающей отторжение трансплантата. Такролимус, ключевой препарат в иммуносупрессии, предупреждает острое и хроническое отторжение трансплантата, подавляя активность Т-лимфоцитов. Он метаболизируется ферментами CYP3A4 и CYP3A5 в печени и кишечнике, а ген CYP3A5 имеет генетические вариации, влияющие на уровень ферментной активности и скорость метаболизма препарата.

**Цель исследования:** анализ современных данных о влиянии полиморфизмов гена CYP3A5 на фармакокинетику и эффективность такролимуса при трансплантации почки

**Методы:** в обзоре проанализированы 46 из 141 публикации из баз данных PubMed, MEDLINE, Embase, Scopus и Cochrane Library, соответствующие критериям включения и посвященные роли полиморфизмов гена CYP3A5 в метаболизме такролимуса у пациентов после трансплантации почки.

**Результаты** показали, что полиморфизмы гена CYP3A5 значительно влияют на фармакокинетику такролимуса. У носителей аллеля \*1 (экспрессоров) отмечался ускоренный метаболизм, требующий увеличения доз, тогда как у пациентов с генотипом \*3/\*3 (неэкспрессоров) метаболизм замедлен, что снижает дозы, но повышает риск токсичности, включая нефротоксичность. Анализ 46 публикаций и данных рандомизированных исследований подтвердил, что генотипирование CYP3A5 позволяет персонализировать дозирование такролимуса. У экспрессоров генотипирование обеспечивало более быстрый выход на терапевтические концентрации, а у неэкспрессоров снижало риск токсических эффектов. Однако долгосрочные различия в клинических исходах между группами с генотипированием и без него остаются статистически незначимыми, что подчеркивает необходимость масштабных исследований для подтверждения эффективности данного подхода.

**Заключение:** Полиморфизмы гена CYP3A5 играют ключевую роль в персонализации иммуносупрессивной терапии у пациентов после трансплантации почки. Генотипирование CYP3A5 позволяет индивидуализировать дозирование такролимуса, снижая риск отторжения трансплантата и токсических эффектов. Внедрение фармакогенетического тестирования в клиническую практику может значительно улучшить долгосрочные исходы трансплантации.

**Ключевые слова:** такралимус, ген CYP3A5, трансплатация почки, иммуносупрессия, генотипирование.

**GENETIC DETERMINANTS OF TACROLIMUS METABOLISM ASSOCIATED WITH CYP3A5 IN KIDNEY TRANSPLANTATION: A LITERATURE REVIEW**

**A.T. Aubakirova, I.K. Madadov, B.G. Rgebayev**
“National Scientific Center of Surgery named after A.N.Syzganov” JSC, Almaty, the Republic of Kazakhstan.

**Abstract**

**Relevance:** Kidney transplantation is the most effective treatment for end-stage chronic kidney disease, significantly improving quality of life and reducing mortality compared to dialysis. Transplant success depends on HLA compatibility between donor and recipient, the level of immune sensitization, the state of the immune system, and the selection of immunosuppressive therapy to prevent graft rejection. Tacrolimus, a key drug in immunosuppressive therapy, prevents acute and chronic rejection by suppressing T-cell activity. It is metabolized by CYP3A4 and CYP3A5 enzymes in the liver and intestines, with the CYP3A5 gene exhibiting genetic variations that influence enzyme activity and the rate of drug metabolism.

**Objective:** To analyze current data on the impact of CYP3A5 gene polymorphisms on the pharmacokinetics and effectiveness of tacrolimus in kidney transplantation.

**Methods:** The review analyzed 46 out of 141 publications from PubMed, MEDLINE, Embase, Scopus, and Cochrane Library databases that met inclusion criteria and focused on the role of CYP3A5 gene polymorphisms in tacrolimus metabolism in kidney transplant patients.

**Results:** CYP3A5 gene polymorphisms significantly affect tacrolimus pharmacokinetics. Carriers of the \*1 allele (expressers) demonstrated accelerated metabolism requiring higher doses, while patients with the \*3/\*3 genotype (non-expressers) exhibited slower metabolism, allowing for reduced doses but increasing the risk of toxicity, including nephrotoxicity. An analysis of 46 publications and randomized studies confirmed that CYP3A5 genotyping enables personalized tacrolimus dosing. For expressers, genotyping facilitated faster achievement of therapeutic concentrations, while for non-expressers, it reduced the risk of toxic effects. However, long-term differences in clinical outcomes between groups with and without genotyping remain statistically insignificant, emphasizing the need for larger-scale studies to validate this approach's efficacy.

**Conclusion:** CYP3A5 gene polymorphisms play a key role in personalizing immunosuppressive therapy for kidney transplant patients. CYP3A5 genotyping allows for individualized tacrolimus dosing, reducing the risk of graft rejection and toxic effects. The implementation of pharmacogenetic testing in clinical practice could significantly improve long-term transplantation outcomes.

**Keywords:** tacrolimus, CYP3A5 gene, kidney transplantation, immunosuppression, genotyping.

**БҮЙРЕК ТРАНСПЛАНТАЦИЯСЫНДАҒЫ CYP3A5-ПЕН БАЙЛАНЫСТЫ ТАКРОЛИМУС МЕТАБОЛИЗМІНІҢ ГЕНЕТИКАЛЫҚ ДЕТЕРМИНАНТТАРЫ: ӘДЕБИЕТКЕ ШОЛУ**

**А.Т. Аубакирова, И.К. Мададов, Б.Г. Ргебаев**

 «А.Н. Сызғанов атындағы Ұлттық хирургия ғылыми орталығы» АҚ, Алматы, Қазақстан Республикасы;

**Андатпа**

**Өзектілігі:** Бүйрек трансплантациясы — терминалдық созылмалы бүйрек жеткіліксіздігін емдеудің ең тиімді әдісі, бұл диализге қарағанда өмір сүру сапасын едәуір жақсартып, өлім-жітімді азайтады. Трансплантацияның табысты болуы донор мен реципиент арасындағы HLA сәйкестігіне, иммундық сенсибилизация деңгейіне, пациенттің иммундық жүйесінің күйіне және трансплантаттың қабылданбауын болдырмауға бағытталған иммуносупрессивтік терапияны дұрыс таңдауға байланысты. Такролимус — Т-лимфоциттердің белсенділігін басу арқылы трансплантаттың жедел және созылмалы қабылданбауын алдын алатын иммуносупрессивтік терапияның негізгі препараты. Ол бауыр мен ішекте CYP3A4 және CYP3A5 ферменттері арқылы метаболизденеді, ал CYP3A5 гені фермент белсенділігі мен препараттың метаболизм жылдамдығына әсер ететін генетикалық вариацияларға ие.

**Зерттеудің мақсаты:** CYP3A5 генінің полиморфизмдерінің такролимустың фармакокинетикасы мен тиімділігіне бүйрек трансплантациясы кезіндегі әсерін талдау.

**Әдістер:** PubMed, MEDLINE, Embase, Scopus және Cochrane Library дерек қорларынан алынған 141 жарияланымның ішінен іріктеу критерияларына сәйкес келетін және CYP3A5 генінің полиморфизмдерінің бүйрек трансплантациясынан кейінгі науқастардағы такролимустың метаболизміне әсеріне арналған 46 жарияланымдары талданылды.

**Нәтижелер:** CYP3A5 генінің полиморфизмдері такролимустың фармакокинетикасына елеулі әсер етеді. \*1 аллельді тасымалдаушыларда (экспрессорлар) препараттың тез метаболизденуі байқалды, бұл жоғары дозаны қажет етті, ал \*3/\*3 генотипі бар науқастарда (экспрессорлар емес) баяу метаболизм анықталып, төмен дозалар жеткілікті болды, бірақ нефротоксиктілік сияқты жағымсыз әсерлердің қаупі артты. 46 жарияланым мен рандомизацияланған зерттеулерді талдау CYP3A5 генотиптеуі такролимустың дозасын жекелендіруге мүмкіндік беретінін көрсетті. Экспрессорларда генотиптеу терапиялық концентрацияларға тезірек жетуді қамтамасыз етті, ал экспрессорлары жоқ уытты әсерлердің қаупін азайтты. Алайда, генотиптеу жүргізілген және жүргізілмеген топтар арасындағы ұзақ мерзімді клиникалық нәтижелердегі айырмашылықтар статистикалық тұрғыдан маңызды емес болып қалды, бұл тәсілдің тиімділігін растау үшін ірі зерттеулер қажеттігін көрсетеді.

**Қорытынды:** CYP3A5 генінің полиморфизмдері бүйрек трансплантациясынан кейінгі науқастарда иммуносупрессивтік терапияны жекелендіруде маңызды рөл атқарады. CYP3A5 генотиптеуі такролимустың дозасын жекелендіруге, трансплантат қабылданбауының және уытты әсерлердің қаупін азайтуға мүмкіндік береді. Фармакогенетикалық тестілеуді клиникалық практикаға енгізу трансплантацияның ұзақ мерзімді нәтижелерін едәуір жақсарта алады.

**Түйін сөздер:** такролимус, CYP3A5 гені, бүйрек трансплантациясы, иммуносупрессия, генотиптеу.

**GENETIC DETERMINANTS OF TACROLIMUS METABOLISM ASSOCIATED WITH CYP3A5 IN KIDNEY TRANSPLANTATION: A LITERATURE REVIEW**

**Introduction**

Between 2012 and 2023, 2,475 organ transplants were performed in Kazakhstan, of which 1,833 were kidney transplants [1]. This method is the most effective treatment for end-stage chronic kidney disease, improving quality of life and reducing mortality compared to dialysis [2]. The success of transplantation depends on HLA compatibility between donor and recipient, the level of immune sensitization, and the selection of immunosuppressive therapy to prevent graft rejection. A personalized approach to treatment, including therapy optimization and dynamic follow-up, improves long-term outcomes [3].

Tacrolimus is a key immunosuppressive agent that prevents acute and chronic rejection of transplanted organs. This calcineurin inhibitor suppresses T-cell activity, reducing immune response. It is metabolized by CYP3A4 and CYP3A5 enzymes, the expression of which is determined by genetic variations in the CYP3A5 gene [4, 5]. The primary polymorphisms of CYP3A5 (\*1 and \*3) determine differences in tacrolimus metabolism. Carriers of the \*1 allele ("expressors") exhibit accelerated metabolism, requiring higher doses, while carriers of the \*3/\*3 genotype ("non-expressors") have slower metabolism, allowing dose reductions but increasing the risk of toxicity [6].

Genotyping CYP3A5 enables individualized tacrolimus dosing, reducing the risk of rejection and side effects. Adjusting therapy based on pharmacogenetic testing improves the safety and efficacy of transplantation.

**Objective:** To analyze current data on the impact of CYP3A5 gene polymorphisms on tacrolimus pharmacokinetics and efficacy in kidney transplantation.

**Materials and Methods:** This review analyzed 46 of 141 publications from PubMed, MEDLINE, Embase, Scopus, and Cochrane Library databases, focusing on the role of CYP3A5 gene polymorphisms in tacrolimus metabolism among kidney transplant recipients. Keywords used included "CYP3A5," "tacrolimus," "pharmacokinetics," "kidney transplantation," "immunosuppression," and "genetic polymorphisms."

**Inclusion criteria:** Studies addressing CYP3A5 polymorphisms and their association with tacrolimus dosing and effects, published in peer-reviewed journals within the last 10 years.
**Exclusion criteria:** Studies without data on CYP3A5, unrelated to transplantation, or published over 10 years ago.

The analysis followed PRISMA guidelines, focusing on the effects of CYP3A5 on metabolism, clearance, tacrolimus concentration, and clinical outcomes such as rejection and toxicity. This research was conducted as part of the scientific project BR24992769 "Development of tissue and organ replacement technologies for the restoration of organ functions in the treatment of gastrointestinal, liver, and kidney diseases." No conflicts of interest were identified.

**Results**

The introduction of calcineurin inhibitors such as cyclosporine (CsA) and tacrolimus (Tac) marked a significant milestone in transplantation, greatly improving patient and graft survival. CsA, derived from the fungus *Tolypocladium inflatum* and first used by Sir Roy Calne in 1987, reduced the rate of acute rejection to 15% and increased the one-year survival rate of kidney transplant recipients to 85% [7, 8]. Its success became the foundation for its use in liver, heart, and other organ transplantation.

CsA acts by binding to cyclophilin, inhibiting calcineurin, and preventing T-cell activation, thereby reducing immune response and lowering the risk of graft rejection [9]. Tacrolimus, a macrolide, was identified in the 1990s from the bacterium *Streptomyces tsukubaensis*. Its clinical use began with liver transplantation under the guidance of Thomas Starzl, after which Tac became widely adopted in kidney, heart, and lung transplantation [10]. Tac has shown superior efficacy compared to CsA, making it a cornerstone of modern immunosuppressive protocols.

Unlike CsA, Tac binds to FK506-binding protein, which also interacts with calcineurin. Similar to CsA, Tac blocks calcineurin, preventing NFAT translocation to the nucleus and inhibiting the expression of cytokines such as interleukin-2 (IL-2). However, Tac has several advantages, including higher efficacy at lower doses, reduced risk of toxic effects, induction of apoptosis in antigen-specific activated T cells, suppression of IL-10 production (reducing antibody production by B cells), and inhibition of TGF-β, which prevents fibrosis in kidney transplants [11, 12]. Despite similarities to CsA, Tac has a more favorable safety profile, including a lower risk of fibrosis and the ability to be used at lower doses [13]. Consequently, the international KDIGO guidelines in 2009 recommended Tac as the first-line agent for initial and maintenance immunosuppressive therapy after kidney transplantation [14].

Comparative studies between CsA and Tac in transplantation are well-documented in the literature. An analysis of data from PubMed, Cochrane Collaboration Resources, and Google Scholar since 2005 identified four meta-analyses of randomized controlled trials (RCTs) evaluating the efficacy and safety of these drugs [15–18]. Key primary outcomes included acute rejection rates and graft loss, while secondary outcomes encompassed insulin-dependent diabetes mellitus (IDDM), nephropathy, hypercholesterolemia, and hypertension [19]. Tac demonstrated significant advantages over CsA, including lower acute rejection rates and improved long-term graft survival. However, Tac was more frequently associated with IDDM due to its impact on pancreatic β-cells, while the incidence of nephropathy and hypertension was similar for both drugs [20].

Tacrolimus, a lipophilic macrolide, is metabolized by CYP3A4 and CYP3A5 enzymes, leading to substantial individual variability in its pharmacokinetics [21]. Tacrolimus bioavailability ranges from 10% to 40%, depending on CYP3A activity. CYP3A5*1 carriers (expressors) require higher doses due to accelerated metabolism, while CYP3A5*3 carriers (non-expressors) have slower metabolism, increasing the risk of toxicity [22, 23]. With a prolonged half-life (12–24 hours), Tac can be administered once or twice daily, facilitating treatment adherence [24]. Tac inhibits calcineurin, preventing NFAT activation and IL-2 transcription, ensuring robust immunosuppressive effects and reducing graft rejection risks [25].

Tac also inhibits TGF-β, preventing fibrosis, induces apoptosis in activated T cells, and suppresses IL-10 production, reducing B-cell activation and humoral rejection risks [26–27]. However, its narrow therapeutic window necessitates regular monitoring to minimize adverse effects [28]. Common side effects of Tac include diabetes mellitus (due to effects on pancreatic β-cells), nephrotoxicity, and hypertension, which require careful management [29–30].

Tacrolimus is a critical immunosuppressive drug in transplantation medicine for preventing organ rejection. Its pharmacokinetics are characterized by low and highly variable bioavailability, complicating therapy individualization. Tacrolimus bioavailability ranges from 5% to 90%, with an average of approximately 25% [31–33]. This variability is driven by absorption characteristics in the gastrointestinal tract and extensive metabolism by the cytochrome P450 system. Tac is predominantly metabolized by CYP3A5 and CYP3A4, with minor contributions from CYP3A7 and CYP3A43, which are expressed in organs such as the small intestine, liver, and kidneys [34]. The small intestine plays a crucial role in the presystemic biotransformation of Tac, while the liver is the primary site of systemic metabolism, which regulates its pharmacokinetics [35].

Once in systemic circulation, approximately 99% of Tac binds to erythrocytes, resulting in whole blood concentrations 10–30 times higher than plasma levels. For its immunosuppressive action, Tac must be in a free, dissociated form, highlighting the importance of factors influencing its metabolism, distribution, and lymphatic penetration [36]. CYP3A5 enzymes in the kidneys can limit Tac accumulation in tissues, leading to discrepancies between blood and tissue concentrations, potentially reducing efficacy and increasing toxicity risks [37–38].

Drug interactions and genetic variations in CYP3A expression further impact Tac bioavailability. CYP3A5 polymorphisms significantly contribute to pharmacokinetic variability and efficacy among different ethnic groups [39]. These challenges complicate achieving stable therapeutic Tac concentrations, increasing the risk of graft rejection or adverse effects. Optimizing therapy requires consideration of key determinants of Tac bioavailability, metabolism, and distribution. A deeper understanding of Tac pharmacodynamics, pharmacokinetics, and pharmacogenetics will enable personalized treatment approaches, crucial for transplant patients [39].

Multiple factors influence Tac nephrotoxicity risk, including donor age, donor sex (males are more susceptible), recipient age, recipient body mass index, cold ischemia time, HLA mismatching, donor hypertension, recipient atherosclerosis, diabetes, and infectious complications. Recipient CYP3A5 genotype, particularly the \*3/\*3 allele, is also a significant risk factor [40–41]. A meta-analysis of 12 prospective studies by Xia T et al. identified donor age, recipient atherosclerosis, and the CYP3A5 \*3/\*3 genotype as key risk factors for acute Tac nephrotoxicity [42].

The CYP3A5 gene, which encodes its eponymous enzyme, has two primary alleles: \*1 and \*3. Patients with the homozygous CYP3A5 \*3/\*3 genotype lack functional enzyme activity, leading to slower Tac metabolism and lower dose requirements. Conversely, carriers of the \*1/\*1 or \*1/\*3 alleles exhibit higher enzyme expression, necessitating higher Tac doses to achieve therapeutic levels. On average, expressors require 50% higher doses than non-expressors, emphasizing the importance of genotyping for individualized Tac dosing. However, genotyping is rarely used in routine clinical practice, with Tac doses typically adjusted based on body weight and therapeutic drug monitoring [43–44].

Despite the evident impact of CYP3A5 genotype on Tac dosing, the feasibility of pre-transplant genotyping in clinical practice remains under evaluation. Pre-transplant genotyping could help calculate optimal doses in advance, particularly in the early post-transplant period when rejection and toxicity risks are highest [45–47].

Таблица 1. Frequency of CYPA5 alleles in different ethnic populations

|  |
| --- |
| **Frequency of CYP3A5 allele** |
| **Ethnic population** | **CYP3A5 \*1/\*1 (%)** | **CYP3A5 \*1/\*3 (%)** | **CYP3A5 \*3/\*3 (%)** |
| Caucasian | 1 | 13–17 | 82–86 |
| Black | 37–45 | 40–54 | 9–15 |
| Indian | 2.5–11 | 38–57 | 32–60 |
| Chinese | 7.7 | 44.8 | 47.4 |
| **Notes:** [23, 27, 40-46]. |

Two randomized studies investigated the potential use of genotyping to optimize Tac dosing. The first study, conducted in France (n=280) [32], included patients whose Tac doses were calculated based on body weight (0.20 mg/kg) and genotype (expressors received 0.30 mg/kg, while non-expressors received 0.15 mg/kg). The second study, conducted in the Netherlands (n=240) [28], employed a similar design but differed in the timing of therapy initiation. In the French study, Tac therapy started on the seventh day, allowing patients with genotyping to achieve target drug concentrations (10–15 ng/mL) more quickly. The Dutch study found no statistically significant differences between the groups but confirmed the influence of the CYP3A5 genotype on Tac dose dependence.

These studies underscore the need for further research to evaluate the clinical utility of genotyping. Larger and more prolonged randomized studies are required to assess the feasibility of implementing pre-transplant genotyping and its impact on transplant therapy outcomes [19].

**Discussion**
The discovery and development of calcineurin inhibitors, such as cyclosporine and tacrolimus, have profoundly impacted the field of transplantation, significantly improving recipient and graft survival rates. Tacrolimus, with its unique properties, has become a cornerstone of modern immunosuppressive protocols, underscoring its clinical relevance in organ transplantation.

The side effects and interindividual variability in the pharmacokinetics and pharmacodynamics of tacrolimus highlight the need for personalized treatment approaches. Pharmacogenetic studies, particularly those evaluating CYP3A5 polymorphisms, play a crucial role in optimizing tacrolimus dosing. Personalization of immunosuppressive therapy, combined with regular drug concentration monitoring, is key to minimizing complications and improving long-term outcomes for organ transplant patients.

The CYP3A5 gene, which encodes a protein belonging to the cytochrome P450 superfamily, plays a critical role in the metabolism of drugs, including tacrolimus, as well as in the synthesis of steroid hormones and other lipids. Cytochrome P450 proteins are monooxygenases that catalyze oxidation reactions essential for drug biotransformation, cholesterol synthesis, and the metabolism of steroids and vitamins. The CYP3A5 gene is located on chromosome 7q21.1 and is part of a cytochrome P450 gene cluster, which includes two pseudogenes. The expression of CYP3A5 varies among populations and is regulated by single-nucleotide polymorphisms (SNPs), which can affect drug metabolism efficiency and predisposition to conditions such as hypertension.

In the context of tacrolimus metabolism, CYP3A5 plays a central role in the biotransformation of the drug, determining its pharmacokinetic parameters. Tacrolimus, widely used as an immunosuppressive agent to prevent graft rejection, presents challenges in dose individualization due to its low and variable bioavailability. The CYP3A5 protein catalyzes the hydroxylation of carbon-hydrogen bonds and participates in the presystemic biotransformation of tacrolimus, leading to its extensive first-pass metabolism in the small intestine and liver. Additionally, this enzyme facilitates the oxidative conversion of xenobiotics, such as tacrolimus and cyclosporine, affecting their pharmacokinetics.

The CYP3A5 gene has two main alleles, \*1 and \*3, which influence the enzyme's expression level. Patients with the \*3/\*3 genotype (non-expressors) exhibit significantly reduced CYP3A5 activity, leading to slower tacrolimus metabolism and a lower dose requirement. Conversely, carriers of the \*1 allele (heterozygotes or homozygotes) show higher enzyme expression, resulting in faster tacrolimus metabolism and the need for higher doses to achieve therapeutic levels. Thus, genetic differences in CYP3A5 are a critical determinant of interindividual variability in tacrolimus pharmacokinetics.

The functional activity of CYP3A5 is essential not only for tacrolimus metabolism but also for the conversion of steroid hormones, such as testosterone and progesterone, as well as the synthesis of catecholestrogens and retinoic acid. The high catalytic activity of CYP3A5 enables it to metabolize 17β-estradiol and estrone, along with xenobiotics such as nifedipine. For tacrolimus, CYP3A5 catalyzes its hydroxylation, resulting in metabolites that limit the drug's bioavailability. Furthermore, CYP3A5 contributes to the oxidative clearance of tacrolimus, which is particularly important for hepatic and renal clearance in post-transplant patients.

CYP3A5 expression is regulated by SNPs, which can influence tacrolimus metabolism and the efficacy and toxicity of other drugs. These genetic variations may also dictate the body's response to tacrolimus therapy, emphasizing the importance of considering pharmacogenetic data when personalizing treatment. Given the significance of CYP3A5 in tacrolimus metabolism, implementing pre-transplant genotyping could facilitate more precise dose adjustments, reducing toxicity risk and enhancing therapeutic efficacy.

In conclusion, the CYP3A5 gene and its polymorphisms are pivotal factors influencing the pharmacokinetic properties of tacrolimus, including its metabolism, bioavailability, and individual dose requirements. This makes CYP3A5 a key target for research in personalized transplantation medicine.

**Conclusion:**
Kidney transplantation in Kazakhstan is a vital area of medical care that significantly improves the quality of life for patients with end-stage chronic kidney failure. Immunosuppression using tacrolimus plays a key role in preventing graft rejection; however, its pharmacokinetic variability requires a meticulous approach to dosage selection. Genetic factors, such as the polymorphism of the CYP3A5 gene, significantly influence the metabolism and bioavailability of tacrolimus, underscoring the importance of incorporating genotyping into clinical practice. Pre-transplant genotyping can facilitate individualized therapy, reducing the risk of toxicity and rejection, while enhancing treatment efficacy.

It is anticipated that further scientific research in this area will contribute to the development of more accurate and accessible genotyping algorithms, strengthening the scientific and practical foundation of transplantology in Kazakhstan. Integrating these approaches into routine clinical practice will be a significant step toward personalized medicine, enabling consideration of individual patient characteristics and minimizing post-transplant complications.

Our literature review highlights the necessity of further investigating the role of genetic factors, including CYP3A5 gene polymorphism, in tacrolimus metabolism. These studies will not only deepen the understanding of the pharmacogenetics of the drug but also help design more effective treatment strategies, ultimately reducing the incidence of complications and extending the functional lifespan of the graft in patients in Kazakhstan.

Tacrolimus, due to its unique pharmacological properties, remains the first-line drug in modern transplantology. However, its use requires careful monitoring, study of pharmacogenetic factors, and an individualized approach to treatment, enabling the minimization of side effects and enhancement of immunosuppressive therapy efficacy.

**REFERENCES**

1. Ministry of the Republic of Kazakhstan news dated October 10, 2023. 2475 organ transplants conducted in Kazakhstan over the last 10 years. [В КАЗАХСТАНЕ ПРОВЕДЕНО 2475 ТРАНСПЛАНТАЦИЙ ОРГАНОВ ЗА ПОСЛЕДНИЕ 10 ЛЕТ](https://www.gov.kz/memleket/entities/dsm/press/news/details/633699?lang=ru&utm_source=chatgpt.com)
2. Baymakhanov B.B., Chormanov A.T., Madadov I.K., Belgibayev E.B., Syrimov ZH.M., Dabyltayeva K.S., Nabiyev E.S., Saduakas N.T., Baiyz A.ZH., Aipov B.R. Graft survival after kidney transplantation from living-related and cadaveric donors// BULLETIN OF SURGERY IN KAZAKHSTAN. 2021. - № 2. – С.5-15. [vestnik\_2\_2021.pdf](https://vhk.kz/wp-content/uploads/2021/04/vestnik_2_2021.pdf)
3. Starzl T.E. History of Clinical Transplantation //World journal of surgery. – 2000. – V.24 (7). P.759-782. <https://doi.org/10.1007/s002680010124>
4. Sabbatini M. et al. Nutritional management in renal transplant recipients: a transplant team opportunity to improve graft survival. // Nutr. Metab. Cardiovasc. – 2019. - Dis. 29. – P. 319–324. <https://doi.org/10.1016/j.numecd.2019.01.002>
5. Vadcharavivad S., Saengram W., Phupradit A., Poolsup N. & Chancharoenthana W. Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies //Drugs. - 2019. - Volume 79. – P. 1947–1962. <https://doi.org/10.1007/s40265-019-01217-7>
6. Degraeve A.L., Bindels L.B, Haufroid V., Moudio S., Boland L., Delongie K.A., Dewulf J. P., Eddour D.C., Mourad M., Elens L. Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross-Sectional Study // Clinical pharmacology@ Therapeutics. - 2024.-V. 115(1). – P.104-115. <https://doi.org/10.1002/cpt.3077>
7. Kim, Joshua S.А., Sze С., Barbar, Tarekc, Lee, John R. New insights into the microbiome in kidney transplantation //Current Opinion in Organ Transplantation. 2021. - 26(6). – p. 582-586. <https://doi.org/10.1097/mot.0000000000000921>
8. Calne R. Y. Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial / Calne R. Y., Wood A. J. //The Lancet. – 1985. – Vol. 326. – №. 8454. – P. 549. 97.
9. Shumakov V.I. Achievements and prospects for the development of transplantology and artificial organs in Russia /V.I. Shumakov // Bulletin of Transplantology and Artificial Organs– 2005. – № 3. – P. 6-9. 98.
10. Starzl T. E. FK 506 for liver, kidney, and pancreas transplantation /Starzl, T., Fung, J., Venkataramman, R [et al.] //The Lancet. – 1989. – Vol. 334. – №. 8670. – P. 1000-1004.
11. Hošková L. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension /Hošková, L., Málek, I., Kopkan, L. [et al.] //Physiological research. – 2017. – Vol. 66. – №. 2. – P. 167. 100.
12. Kamińska D. The influence of warm ischemia elimination on kidney injury during transplantation–clinical and molecular study /Kamińska, D., KościelskaKasprzak, K., Chudoba, P [et al.] //Scientific Reports. – 2016. – Vol. 6. – №. 1. – P. 1-10.
13. Webster A.C.. Woodroffe R.C., Taylor R.S., Chapman J.R., Craig J. C.Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data // BMJ. – 2005. –.331 doi: <https://doi.org/10.1136/bmj.38569.471007.AE>
14. Kasiske B. L. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary /Kasiske, B. L., Zeier, M. G., Chapman, J. R. [et al.] //Kidney international. – 2010. – Vol. 77. – №. 4. – P. 299-311.
15. Yu M. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation / Yu, M., Liu, M., Zhang, W. [et al.] //Current drug metabolism. – 2018. – Vol. 19. – №. 6. – P. 513-522.
16. Azarfar A. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis /Azarfar, A., Ravanshad, Y., Mehrad-Majd, H. [et al.] //Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. – 2018. – Vol. 29. – №. 6. – P. 1376-1385.
17. Liu J. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation / Liu, J. Y., You, R. X., Guo, M. [et al.] //American journal of therapeutics. – 2016. – Vol. 23. – №. 3. – P. e810-e824.
18. Ravanshad Y. A comparison between tacrolimus and cyclosporine as immunosuppression after renal transplantation in children, a meta-analysis and systematic review /Ravanshad, Y., Azarfar, A., Ravanshad, S. [et al.] //Iranian Journal of Kidney Diseases. – 2020. – Vol. 14. – №. 2. – P. 145.
19. Chen L., Prasad G.V. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment // Pharmacogenomics And Personalized Medicine Journal. – 2018. – Volume 11. – P.23—33. DOI <https://doi.org/10.2147/PGPM.S107710>
20. Shuker N. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management / Shuker N., van Gelder T., Hesselink D. A. //Transplantation Reviews. – 2015. – Vol. 29. – №. 2. – P. 78-84.
21. Birdwell KA, Decker B, Barbarino JM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. //Clin Pharmacol Ther. – 2015. - 98(1). – Р. 19–24. <https://doi.org/10.1002/cpt.113>
22. Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5\*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. //Pharmacogenomics J. -2015. - 15(1). –Р.38–48. <https://doi.org/10.1038/tpj.2014.38>
23. Tang JT, Andrew LM, van Gelder T, et al. Pharmacogenetics aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations// Expert Opin Drug Metab Toxicol. – 2016. - 12(5). – Р.555–565. <https://doi.org/10.1517/17425255.2016.1170808>
24. Chen P, Li J, Li J, et al. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. //J Clin Pharm Ther. – 2017. - 42(1). Р.93–97. <https://doi.org/10.1111/jcpt.12480>
25. Sallustio B. C. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients / Sallustio, B. C., Noll, B. D., Hu, R. [et al.] //British Journal of Clinical Pharmacology. – 2021. – Vol. 87. – №. 10. – P. 3901-3909. <https://doi.org/10.1111/bcp.14806>
26. Vanhove T. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review / Vanhove T., Annaert P., Kuypers D. R. J. //Drug metabolism reviews. – 2016. – Vol. 48. – №. 1. – P. 88-112. <https://doi.org/10.3109/03602532.2016.1151037>
27. Xia T. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis / Xia, T., Zhu, S., Wen, Y. [et al.] //Drug Design, Development and Therapy. – 2018. – Vol. 12. – P. 417. <https://doi.org/10.2147/dddt.s149340>
28. Shuker N. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype‐ based with body‐ weight‐ based tacrolimus dosing after living donor kidney transplantation / Shuker, N., Bouamar, R., van Schaik, R. H. [et al.] //American Journal of Transplantation. – 2016. – Vol. 16. – №. 7. – P. 2085-2096. <https://doi.org/10.1111/ajt.13691>
29. Birdwell K. A. Supplemental Material Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing / Birdwell, K. A., Decker, B., Barbarino, J. M. [et al.] //Clinical Pharmacology & Therapeutics. – 2015. – Т. 98. – №. 1. – С. 19-24. <https://doi.org/10.1002/cpt.113>
30. Hu R. CYP3A5\* 3 and ABCB1 61A> G significantly influence dose‐ adjusted trough blood tacrolimus concentrations in the first three months post‐ kidney transplantation / Hu, R., Barratt, D. T., Coller, J. K. [et al.] //Basic & Clinical Pharmacology & Toxicology. – 2018. – Vol. 123. – №. 3. – P. 320-326 <https://doi.org/10.1111/bcpt.13016>
31. Kuypers D. R. J. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients / Kuypers, D. R., Naesens, M., de Jonge, H. [et al.] //Therapeutic drug monitoring. – 2010. – Vol. 32. – №. 4. – P. 394-404.
32. Thervet E. Optimization of initial tacrolimus dose using pharmacogenetic testing / Thervet, E., Loriot, M. A., Barbier, S. [et al.] //Clinical Pharmacology & Therapeutics. – 2010. – Vol. 87. – №. 6. – P. 721-726.
33. Thölking G. A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity / Thölking, G., Schütte-Nütgen, K., Schmitz, J. [et al.] //Journal of clinical medicine. – 2019. – Vol. 8. – №. 10. – P. 1586.
34. Zegarska J. Tacrolimus metabolite M-III may have nephrotoxic and myelotoxic effects and increase the incidence of infections in kidney transplant recipients / Zegarska, J., Hryniewiecka, E., Zochowska, D. [et al.] //Transplantation Proceedings. – Elsevier, 2016. – Vol. 48. – №. 5. – P. 1539-1542.
35. Ro H. The tacrolimus metabolism affect post‐ transplant outcome mediating acute rejection and delayed graft function: analysis from Korean Organ Transplantation Registry data / Ro, H., Jeong, J. C., Kong, J. M. [et al.] //Transplant International. – 2021. – Vol. 34. – №. 1. – P. 163-174.
36. West-Thielke P. What's in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers / West-Thielke, P., Maldonado, A., Patel, S. J. [et al.] //American journal of transplantation. – 2019. – Vol. 19. – P. 360-361.
37. Krämer B. K. Efficacy of prolonged-and immediate-release tacrolimus in kidney transplantation: a pooled analysis of two large, randomized, controlled trials / Krämer, B. K., Albano, L., Banas, B. [et al.] //Transplantation Proceedings. – Elsevier, 2017. – Vol. 49. – №. 9. – P. 2040-2049.
38. Glowacki F. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients / Glowacki, F., Lionet, A., Hammelin, J. P. [et al.] //Clinical pharmacokinetics. – 2011. – Vol. 50. – №. 7. – P. 451-459.
39. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015) <https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/>
40. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.// Ther Drug Monit. -2010. -32(6). – P.708–714. <https://doi.org/10.1097/ftd.0b013e3181f3c063>
41. Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5\*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. //Pharmacogenomics J. – 2015. - 15(1). – P.38–48. <https://doi.org/10.1038/tpj.2014.38>
42. Chen P, Li J, Li J, et al. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.// J Clin Pharm Ther. – 2017. - 42(1). – P.93–97. <https://doi.org/10.1111/jcpt.12480>
43. Boughton O, Borgulya G, Cecconi M, Frederick S, Moreton-Clack M, MacPhee IA. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. //Br J Clin Pharmacol. – 2013. - 76(3). – P. 425–431. <https://doi.org/10.1111/bcp.12076>
44. Niioka T, Kagya H, Saito M, et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage postrenal transplantation. //Int J Mol Sci. – 2015. - 16(1). – P.1840–1854. <https://doi.org/10.3390/ijms16011840>
45. Chandel N, Aggarwal PK, Minz M, Sakhuja V, Kohli KK, Jha V. CYP3A5\*1/\*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. //Pharmacogenet Genomics. – 2009. - 19(6). – P.458–463. <https://doi.org/10.1097/fpc.0b013e32832bd085>
46. Satoh S, Saito M, Inoue T, et al. CYP3A5 \*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. //Eur J Clin Pharmacol. – 2009. - 65(5). – P.473–481. <https://doi.org/10.1007/s00228-008-0606-3>

**Author Information:**

**Aubakirova Aigul Toktasynovna** (corresponding author) – Candidate of Biological Sciences, Scientific Secretary, Laboratory Physician of the Clinical and Diagnostic Research Department, JSC "National Scientific Center of Surgery named after A.N. Syzganov," Almaty, Kazakhstan; e-mail: biolog-aigul@mail.ru, phone: +7 701 951 31 92. ORCID ID: <https://orcid.org/0000-0001-7585-2898>.
**Madadov Islam Kurbanovich** – Urologist-Transplantologist, Head of the Department of Kidney Transplantation, Urology, and Extracorporeal Detoxification, JSC "National Scientific Center of Surgery named after A.N. Syzganov," Almaty, Kazakhstan; e-mail: Doctormik89@mail.ru, phone: +7 747 839 71 10. ORCID ID: <https://orcid.org/0000-0003-2241-8603>.
**Rgebayev Berik Galimovich** – Urologist-Transplantologist, Department of Kidney Transplantation, Urology, and Extracorporeal Detoxification, JSC "National Scientific Center of Surgery named after A.N. Syzganov," Almaty, Kazakhstan; e-mail: rgebaevberik@gmail.com, phone: +7 702 529 55 88. ORCID ID: <https://orcid.org/0000-0002-5201-3888>.
**Correspondence Address:** Aubakirova A.T., JSC "National Scientific Center of Surgery named after A.N. Syzganov," 62 Zheltoksan Ave., Almaty 050000, Kazakhstan.

**Contributions of Authors:**

**Contribution to concept:** Aubakirova A.T.

**Scientific design:** Aubakirova A.T.

**Execution of the declared scientific study:** Aubakirova A.T., Madadov I.K., Rgebayev B.G.

**Interpretation of the declared scientific study:** Aubakirova A.T., Madadov I.K., Rgebayev B.G.

**Scientific article preparation:** Aubakirova A.T., Madadov I.K., Rgebayev B.G.

**Funding:** The authors declare no funding for this study.
**Conflict of Interest:** The authors declare no conflicts of interest.